Bausch Health Companies Inc. (BHC) Guidance & Earnings Results

On 2026-07-29 Bausch Health Companies Inc. raised guidance: "FY26 consolidated revenue raised to $10.790-11.040B; BHC ex-B+L revenue $5.350-5.500B; B+L revenue $5.440-5.540B; FY26 consolidated Adjusted EBITDA $4.050-4.175B; BHC ex-B+L Adjusted EBITDA $3.025-3.100B; B+L Adjusted…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BHCBausch Health Companies Inc.Follow BHC — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	FY26 consolidated revenue raised to $10.790-11.040B; BHC ex-B+L revenue $5.350-5.500B; B+L revenue $5.440-5.540B; FY26 consolidated Adjusted EBITDA $4.050-4.175B; BHC ex-B+L Adjusted EBITDA $3.025-3.100B; B+L Adjusted EBITDA $1.025-1.075B; FY26 Adjusted Cash Flows from Operations $1.400-1.475B · full year
29 Apr 26	Reaffirmed	FY2026 revenue $10.670-10.920B; adjusted EBITDA $3.885-4.010B; BHC ex B+L revenue $5.250-5.400B, adjusted EBITDA $2.875-2.950B; B+L revenue $5.420-5.520B, adjusted EBITDA $1.010-1.060B; adjusted cash flow from operations $1.200-1.275B · full year
18 Feb 26	Raised	FY2026 revenue $10.625-10.875B (vs FY2025 $10.266B); Adj. EBITDA $3.875-4.000B (vs FY2025 $3.54B); Adj. Operating Cash Flow $1.200-1.275B; BHC excl. B+L revenue $5.250-5.400B; B+L revenue $5.375-5.475B; BHC excl. B+L Adj. EBITDA $2.875-2.950B; B+L Adj. EBITDA $1.000-1.050B · full year
29 Oct 25	Raised	FY2025 BHC revenue $10.05-10.25B; BHC excl. B+L revenue $5.00-5.10B; B+L revenue $5.05-5.15B; BHC Adj. EBITDA $3.57-3.66B; BHC excl. B+L Adj. EBITDA $2.70-2.75B; B+L Adj. EBITDA $0.87-0.91B; BHC excl. B+L Adj. CFO $0.975-1.025B · full year
30 Jul 25	Raised	FY2025 consolidated revenue raised to $10.0-10.25B; Adj EBITDA raised to $3.485-3.635B; BHC ex B+L reaffirmed: revenue $4.95-5.1B, Adj EBITDA $2.625-2.725B, Adj CFO $0.825-0.875B · full year

Bausch Health Companies Inc. — questions

What guidance did Bausch Health Companies Inc. give?: On 2026-07-29: "FY26 consolidated revenue raised to $10.790-11.040B; BHC ex-B+L revenue $5.350-5.500B; B+L revenue $5.440-5.540B; FY26 consolidated Adjusted EBITDA $4.050-4.175B; BHC ex-B+L Adjusted EBITDA $3.025-3.100B; B+L Adjusted EBITDA $1.025-1.075B; FY26 Adjusted Cash Flows from Operations $1.400-1.475B"
When does Bausch Health Companies Inc. report earnings?: Bausch Health Companies Inc.'s next earnings report is expected on 2026-10-28.

Every figure on this page comes from Bausch Health Companies Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.